Status:
NOT_YET_RECRUITING
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
Lead Sponsor:
Xijing Hospital
Conditions:
Prostatic Neoplasms
Glioma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a study using a parallel control approach and is expected to recruit 35 volunteers, including 8 prostate cancer patients, 8 neuroendocrine tumour patients, 8 glioma patients, 8 Parkinson's syn...
Eligibility Criteria
Inclusion
- Age: 18 \~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index \[BMI = weight (kg)/height 2 (m2)\] within the range of 19.0 \~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma: patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Parkinson's syndrome: patients with high clinical suspicion of Parkinson's syndrome.
- Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.
Exclusion
- Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Under 18 years of age or ECOG score \> 2; Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Women during pregnancy and breastfeeding; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Participation in other interventional clinical trials within 1 month prior to screening; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
Key Trial Info
Start Date :
March 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06914427
Start Date
March 28 2025
End Date
March 1 2027
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China